In short
Clinical trials of Hyaluronidase (Human Recombinant) are studying subcutaneous treatment approaches in people with primary immunodeficiency diseases and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). These trials mainly look at safety, tolerability, and how the treatment behaves in the body, including pharmacokinetics. The studies include adults and older adolescents in different trial phases.
Key points
- Clinical trials of Hyaluronidase (Human Recombinant) are focused on people with primary immunodeficiency diseases and adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The studies include Phase 3 and Phase 4 research, plus one earlier Phase 1 trial in the source data that is not about this substance. The main goals are to check safety, tolerability, and pharmacokinetics, which means how the treatment behaves in the body. Several studies compare TAK-881 with HyQvia after subcutaneous use. The trials also measure outcomes such as treatment-emergent adverse events, infusion-related changes, and total IgG exposure.
Overview of the trial program
The clinical trial data for Hyaluronidase (Human Recombinant) focus on studies of subcutaneous treatment, which means treatment given under the skin. The main trial settings in the source data are primary immunodeficiency diseases and chronic inflammatory demyelinating polyradiculoneuropathy, also called CIDP.
Most of the listed studies are designed to compare TAK-881 with HyQvia, and they look at how the treatment behaves in the body, as well as safety and tolerability. One additional Phase 1 trial in the source data is about subcutaneous durvalumab and is not a Hyaluronidase (Human Recombinant) study.
Trials in primary immunodeficiency diseases
Two trials in the source data are for people with Primary Immunodeficiency Diseases (PIDD), a group of conditions where the immune system does not work properly. These studies include a Phase 3 long-term safety study and a Phase 4 crossover study that compares treatments in older adolescents and adults.
NCT06076642 is a Phase 3 study with 37 enrolled participants and the status listed as Authorised. Its goal is to evaluate long-term safety and tolerability of TAK-881, with primary outcomes that include treatment-emergent adverse events and infusion withdrawals, interruptions, and rate reductions linked to TAK-881-related adverse events.
NCT05755035 is a multicenter, prospective, open-label, randomized, crossover Phase 4 study with 50 enrolled participants and a Completed status. It aims to show pharmacokinetic comparability between TAK-881 and HyQvia at steady-state after subcutaneous administration in subjects aged 16 years and older with PIDD.
In simple terms, this means the researchers are checking whether the two treatments give similar blood exposure over time in the study group. The main endpoint is AUC0-τ,ss based on total IgG levels, which is a way to measure total exposure during a dosing interval at steady-state.
Trials in CIDP
One Phase 3 study in the source data targets adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a long-lasting nerve disorder that can affect strength and movement. This study is listed as Authorised and includes 65 participants.
The study is a single-arm, multiple-dose, pharmacokinetic comparability trial between TAK-881 and HyQvia in adults with CIDP. Its brief summary says the purpose is to show pharmacokinetic comparability after subcutaneous administration in participants with CIDP.
The primary outcome is baseline-uncorrected area under the curve during the dosing interval at steady-state, based on total IgG levels. This tells researchers how much treatment exposure the body has over the dosing period.
What the trials measure
The listed trials measure both safety and pharmacokinetics (PK), which means how the treatment moves through the body.
- Treatment-emergent adverse events (TEAEs): unwanted medical events that happen after treatment starts.
- Infusion withdrawals, interruptions, and rate reductions: these show whether the infusion had to be stopped, paused, or slowed because of treatment-related problems.
- AUC0-τ,ss: a measure of total drug exposure over one dosing interval at steady-state.
- Total IgG levels: the studies use this blood marker to compare exposure between treatments.
Study design and phases
The source data includes Phase 3, Phase 4, and Phase 1 studies, but only the Phase 3 and Phase 4 studies are directly about Hyaluronidase (Human Recombinant) in the provided records.
The PIDD Phase 4 study is described as multicenter, prospective, open-label, randomized, and crossover. These words mean the study was done at more than one center, followed participants forward in time, did not hide the assigned treatment, randomly assigned treatment order, and had participants receive more than one study treatment in sequence.
The CIDP study is single-arm and multiple-dose, which means there is no separate comparison group in the source description and participants receive more than one dose during the study.
What patients should know from the trial data
From the available trial records, Hyaluronidase (Human Recombinant) research is centered on people with immune-related and nerve-related conditions, especially PIDD and CIDP.
The main research questions are whether the study treatments are safe, whether they are tolerated over time, and whether they produce similar exposure in the body when compared with HyQvia.
The source data does not give detailed results, so the article can only describe the study goals, populations, phases, and outcomes that were planned or measured.